Temozolomide and radiation in low-grade and anaplastic gliomas: Temoradiation

Cancer Investigation

Volumn 25, Issue 8, 2007, Pages 776-784

  Schiff, David ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Anaplastic glioma; Astrocytoma; Chemotherapy; Glioma; Molecular markers; Oligodendroglioma; Temozolomide

Indexed keywords

CARMUSTINE; COTRIMAZINE; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NITROSOUREA DERIVATIVE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ADJUVANT THERAPY; ANAPLASTIC CARCINOMA; APLASTIC ANEMIA; BLOOD TOXICITY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CHROMOSOME DELETION; CLINICAL TRIAL; COGNITION; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DRUG MECHANISM; DRUG METABOLISM; FUNCTIONAL STATUS; GLIOBLASTOMA; GLIOMA; HUMAN; IMMUNE DEFICIENCY; IMMUNOHISTOCHEMISTRY; INFECTION; LOW DRUG DOSE; LYMPHOCYTOPENIA; META ANALYSIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; OLIGODENDROGLIOMA; PATIENT SATISFACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METHYLATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SALVAGE THERAPY; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; CLINICAL TRIALS, PHASE III AS TOPIC; COMBINED MODALITY THERAPY; DACARBAZINE; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; GLIOMA; HUMANS; PROMOTER REGIONS (GENETICS); TUMOR SUPPRESSOR PROTEINS;

EID: 36849091882     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900701509403     Document Type: Review

References (60)

1. Denny, B.J.; Wheelhouse, R.T.; Stevens, M.F.; Tsang, L.L.; Slack, J.A. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 1994, 33, 9045-51.
2. Curtin, N.J.; Wang, L.Z.; Yiakouvaki, A.; et al. Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells. Clin. Cancer Res. 2004, 10, 881-9.
3. Ostermann, S.; Csajka, C.; Buclin, T.; et al. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin. Cancer Res. 2004, 10, 3728-36.
4. Patel, M.; McCully, C.; Godwin, K.; Balis FM. Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates. J. Neurooncol. 2003, 61, 203-7.
5. O'Reilly, S.M.; Newlands, E.S.; Glaser, M.G.; et al. Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur. J. Cancer 1993, 29A, 940-2.
6. Yung, W.K.; Prados, M.D.; Yaya-Tur, R., et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J. Clin. Oncol. 1999, 17, 2762-71.
7. Chakravarti, A.; Erkkinen, M.G.; Nestler, U.; et al. Temozolomide- mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Clin. Cancer Res. 2006, 12, 4738-46.
8. Stupp, R.; Dietrich, P.Y.; Ostermann Kraljevic, S.; et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J. Clin. Oncol. 2002, 20, 375-82.
9. Stupp, R.; Mason, W.P.; van den Bent, MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352, 987-96.
10. Fine, H.A.; Dear, K.B.; Loeffler, J.S.; Black, P.M.; Canellos, G.P. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993, 71, 2585-97.
11. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002, 359, 1011-8.
12. Levin, V.A.; Silver, P.; Hannigan, J.; et al. Superiority of postradiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int. J. Radiat. Oncol. Biol. Phys. 1990, 18, 321-4.
13. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J. Clin. Oncol. 2001, 19, 509-18.
14. Prados, M.D.; Scott, C.; Curran, W.J. Jr.; Nelson, D.F.; Leibel, S.; Kramer, S. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: A retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy. J. Clin. Oncol. 1999, 17, 3389-95.
15. Cairncross, G.; Berkey, B.; Shaw, E.; et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J. Clin. Oncol. 2006, 24, 2707-14.
16. van den Bent, M.J.; Carpentier, A.F.; Brandes, A.A.; et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J. Clin. Oncol. 2006, 24, 2715-22.
17. Shaw, E.G.; Berkey, B.;Coons, S.W.; Brachman, D.; Buckner, J.C.; Stelzer, K.J.; Barger, G.R.; Brown, P.D.; Gilbert, M.R.; Mehta, M.P. Initial report of Radiation Therapy Oncology Group (RTOG) 9802: Prospective studies in adult low-grade glioma (LGG). In: 2006 ASCO Annual Meeting; 2006; Atlanta; 2006. p. Abstract 1500.
18. Jaeckle, K.A.; Eyre, H.J.; Townsend, J.J.; et al. Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J. Clin. Oncol. 1998, 16, 3310-5.
19. Costello, J.F.; Futscher, B.W.; Tano, K.; Graunke, D.M.; Pieper, R.O. Graded methylation in the promoter and body of the O6-methylguanine DNA methyltransferase (MGMT) gene correlates with MGMT expression in human glioma cells. J. Biol. Chem. 1994, 269, 17228-37.
20. Alonso, M.E.; Bello, M.J.; Gonzalez-Gomez, P.; et al. Aberrant promoter methylation of multiple genes in oligodendrogliomas and ependymomas. Cancer Genet. Cytogenet. 2003, 144, 134-42.
21. Dong, S.M.; Pang, J.C.; Poon, W.S.; et al. Concurrent hypermethylation of multiple genes is associated with grade of oligodendroglial tumors. J. Neuropathol. Exp. Neurol. 2001, 60, 808-16.
22. Esteller, M.; Hamilton, S.R.; Burger, P.C.; Baylin, S.B.; Herman, J.G. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 1999, 59, 793-7.
23. Gonzalez-Gomez, P., Bello, M.J.; Arjona. D.; et al. Promoter hypermethylation of multiple genes in astrocytic gliomas. Int. J. Oncol. 2003, 22, 601-8.
24. Komine, C.; Watanabe, T.; Katayama, Y.; Yoshino, A.; Yokoyama, T.; Fukushima, T. Promoter hypermethylation of the DNA repair gene O6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas. Brain Pathol. 2003, 13, 176-84.
25. Everhard, S.; Kaloshi, G.; Criniere, E.; et al. MGMT methylation: A marker of response to temozolomide in low-grade gliomas. Ann. Neurol. 2006, 60, 740-3.
26. Esteller, M.; Garcia-Foncillas, J.; Andion, E.; et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 2000, 343, 1350-4.
27. Hegi, M.E.; Diserens, A.C.; Godard, S.; et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin. Cancer Res. 2004, 10, 1871-4.
28. Hegi, M.E.; Diserens, A.C.; Gorlia, T.; et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 2005, 352, 997-1003.
29. Paz, M.F.; Yaya-Tur. R.; Rojas-Marcos, I.; et al. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin. Cancer Res. 2004, 10, 4933-8.
30. Reifenberger, J.; Reifenberger, G.; Liu, L.; James, C.D.; Wechsler, W.; Collins, V.P. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am. J. Pathol. 1994, 145, 1175-90.
31. Cairncross, J.G.; Ueki, K.; Zlatescu. M.C.; et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. Journal of the National Cancer Institute 1998, 90, 1473.
32. Smith, J.S.; Perry, A.; Borell, T.J.; et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J. Clin. Oncol. 2000, 18, 636-45.
33. Felsberg, J.; Erkwoh, A.; Sabel, M.C.; et al. Oligodendroglial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival. Brain Pathol. 2004, 14, 121-30.
34. Okamoto, Y.; Di Patre, P.L.; Burkhard. C.; et al. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta. Neuropathol. (Berl.) 2004, 108, 49-56.
35. Jenkins, R.B.; Blair, H.; Ballman, K.V.; et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res. 2006, 66, 9852-61.
36. Griffin, C.A.; Burger, P.; Morsberger, L.; et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J. Neuropathol. Exp. Neurol. 2006, 65, 988-94.
37. van den Bent, M.J.; Keime-Guibert, F. Brandes, A.A.; et al. Temozolomide chemotherapy in recurrent oligodendroglioma. Neurology 2001, 57, 340-2.
38. van den Bent, M.J.; Taphoorn, M.J.; Brandes, A.A.; et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J. Clin. Oncol. 2003, 21, 2525-8.
39. van den Bent, M.J.; Chinot, O.; Boogerd, W.; et al. Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. Ann. Oncol. 2003, 14, 599-602.
40. Chinot, O.L.; Honore, S.; Dufour, H.; et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J. Clin. Oncol. 2001, 19, 2449-55.
41. Gilbert, M.R.; Friedman, H.S.; Kuttesch, J.F.; et al. A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. Neuro-oncol. 2002, 4, 261-7.
42. Vogelbaum, M.A.; Berkey, B.; Peereboom, D.; et al. RTOG 0131: Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligodendrogliomas. Journal of Clinical Oncology 2005, 23, 1520.
43. Vogelbaum, M.A.; Berkey, B.; Peereboom, D.; et al. RTOG 0131: Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligodendrogliomas: Relationship between 1p/19q status and progression-free survival. Journal of Clinical Oncology 2006, 24, 1517.
44. Peereboom, D.; Brewer, C.; Schiff, D.; et al. Dose-intense temozolomide in patients with newly-diagnosed pure and mixed anaplastic oligodendroglioma: phase II multicenter study. Neuro-Oncology 2006, 8, 448.
45. Quinn, J.A.; Reardon, D.A.; Friedman, A.H.; et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. J. Clin. Oncol. 2003, 21, 646-51.
46. Pace, A.; Vidiri, A.; Galie, E.; et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann. Oncol. 2003, 14, 1722-6.
47. Pouratian, N.; Gasco, J.; Sherman, J.H.; Shaffrey, M.E.; Schiff, D. Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas. J. Neuro-oncol. 2006, 82, 281-288.
48. Soffietti, R.; Ruda, R.; Bradac, G.B.; Schiffer, D. PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery 1998, 43, 1066-73.
49. Stege, E.M.; Kros, J.M.; de Bruin, H.G.; et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer 2005, 103, 802-9.
50. Brada, M.; Viviers, L.; Abson, C.; et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann. Oncol. 2003, 14, 1715-21.
51. Hoang-Xuan, K.; Capelle, L.; Kujas, M.; et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J. Clin. Oncol. 2004, 22, 3133-8.
52. Levin, N.; Lavon, I.; Zelikovitsh, B.; et al. Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer 2006, 106, 1759-65.
53. Pignatti, F.; van den Bent, M.; Curran, D.; et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J. Clin. Oncol. 2002, 20, 2076-84.
54. Gerber, D.E.; Grossman, S.A.; Zeltzman, M.; Parisi, M.A.; Kleinberg. L. The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas. Neuro-oncol 2007, 9, 47-52.
55. Villano, J.L.; Collins, C.A.; Manasanch, E.E.; Ramaprasad, C.; van Besien. K. Aplastic anaemia in patient with glioblastomamultiforme treated with temozolomide. Lancet Oncol. 2006, 7, 436-8.
56. Su, Y.W.; Chang, M.C.; Chiang, M.F.; Hsieh, R.K. Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma. J. Neurooncol. 2005, 71, 315-8.
57. Noronha, V.; Berliner, N.; Ballen, K.K.; et al. Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: case study and review of the literature. Neuro-oncol. 2006, 8, 280-3.
58. Perry, J.R.; Brown, M.T.; Gockerman, J.P. Acute leukemia following treatment of malignant glioma. J. Neurooncol. 1998, 40, 39-46.
59. Tosoni, A.; Cavallo, G.; Ermani, M.; et al. Is protracted low-dose temozolomide feasible in glioma patients? Neurology 2006, 66, 427-9.
60. Ganiere, V.; Christen, G.; Bally, F.; et al. Listeria brain abscess, Pneumocystis pneumonia and Kaposi's sarcoma after temozolomide. Nat. Clin. Pract. Oncol. 2006, 3, 339-43.